Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
BackgroundChina’s southwestern region, Qujing, harbors a high incidence of non-small cell lung cancer (NSCLC) and related mortality. This study was designed to reveal the impact of an immune-related prognostic signature (IRPS) on advanced NSCLC in the Qujing.MethodsTissue specimens from an independe...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1012166/full |
| _version_ | 1797893729230520320 |
|---|---|
| author | Yuhui Ma Hutao Shi Guangqiang Zhao Xin Liu Jingjing Cai Guangjian Li Wanlin Chen Yujie Lei Lianhua Ye Chaojiang Fu Li Zhao Yongchun Zhou Yunchao Huang Yunchao Huang |
| author_facet | Yuhui Ma Hutao Shi Guangqiang Zhao Xin Liu Jingjing Cai Guangjian Li Wanlin Chen Yujie Lei Lianhua Ye Chaojiang Fu Li Zhao Yongchun Zhou Yunchao Huang Yunchao Huang |
| author_sort | Yuhui Ma |
| collection | DOAJ |
| description | BackgroundChina’s southwestern region, Qujing, harbors a high incidence of non-small cell lung cancer (NSCLC) and related mortality. This study was designed to reveal the impact of an immune-related prognostic signature (IRPS) on advanced NSCLC in the Qujing.MethodsTissue specimens from an independent cohort of 37 patients with advanced NSCLC were retrospectively evaluated to determine the relationship between the IRPS estimated by next-generation sequencing (NGS) and clinical outcome. To compare the IRPS in tissue and the clinical outcomes between Qujing and non-Qujing populations, we analyzed datasets of 23 patients with advanced NSCLC from The Cancer Genome Atlas (TCGA) database. In addition, an independent cohort (n=111) of blood specimens was retrospectively analyzed to determine the relationship between the IRPS and clinical outcome. Finally, we evaluated the utility of the blood IRPS in classifying 24 patients with advanced NSCLC who might benefit from immunotherapy.ResultsIn cohort 1, the Qujing population with tTMB-H (≥ 10 mutations/Mb) or KRAS mutations had shorter progression-free survival (PFS) (hazard ratio [HR] 0.37, 0.14 to 0.97, P = 0.04; HR 0.23, 0.08 to 0.66, P < 0.01) and overall survival (OS) (HR 0.05, 0.01 to 0.35, P < 0.01; HR 0.22, 0.07 to 0.66, P < 0.01). In cohort 2 of the Qujing population, bTMB-H (≥ 6 mutations per Mb) and KRAS mutations were related to PFS (HR 0.59, 0.36 to 0.99, P = 0.04; HR 0.50, 0.26 to 0.98, P = 0.04) and OS (HR 0.58, 0.35 to 0.96, P = 0.03; HR 0.48, 0.25 to 0.93, P = 0.03). Notably, the Qujing population with bTMB-H had superior PFS (HR 0.32, 0.09 to 1.09, P = 0.01), OS (HR 0.33, 0.10 to 1.13, P < 0.01) and objective response rates (ORRs) (83.3% vs. 14.3% vs. 20.0%, P <0.01) to immunotherapy than other populations.ConclusionsThese findings show that tTMB, bTMB and KRAS mutations appear to be independent validated IRPSs that predict the clinical outcomes of Qujing populations with advanced NSCLC and that bTMB may be used as a reliable IRPS to predict the clinical benefit from anti-PD-1 therapies among populations from Qujing with advanced NSCLC. |
| first_indexed | 2024-04-10T06:57:34Z |
| format | Article |
| id | doaj.art-c8ce58c908534506820a59021c130f46 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T06:57:34Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c8ce58c908534506820a59021c130f462023-02-28T06:47:03ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10121661012166Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest ChinaYuhui Ma0Hutao Shi1Guangqiang Zhao2Xin Liu3Jingjing Cai4Guangjian Li5Wanlin Chen6Yujie Lei7Lianhua Ye8Chaojiang Fu9Li Zhao10Yongchun Zhou11Yunchao Huang12Yunchao Huang13Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaDepartment of Imaging at Kunming Tongren Hospital, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaYunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, ChinaYunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaEmergency Department (Outpatient Chemotherapy Center) at Yunnan Cancer Hospital, Kunming, ChinaDepartment of Anesthesiology at Yunnan Cancer Hospital, Kunming, ChinaYunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, ChinaDepartment of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, ChinaYunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, ChinaBackgroundChina’s southwestern region, Qujing, harbors a high incidence of non-small cell lung cancer (NSCLC) and related mortality. This study was designed to reveal the impact of an immune-related prognostic signature (IRPS) on advanced NSCLC in the Qujing.MethodsTissue specimens from an independent cohort of 37 patients with advanced NSCLC were retrospectively evaluated to determine the relationship between the IRPS estimated by next-generation sequencing (NGS) and clinical outcome. To compare the IRPS in tissue and the clinical outcomes between Qujing and non-Qujing populations, we analyzed datasets of 23 patients with advanced NSCLC from The Cancer Genome Atlas (TCGA) database. In addition, an independent cohort (n=111) of blood specimens was retrospectively analyzed to determine the relationship between the IRPS and clinical outcome. Finally, we evaluated the utility of the blood IRPS in classifying 24 patients with advanced NSCLC who might benefit from immunotherapy.ResultsIn cohort 1, the Qujing population with tTMB-H (≥ 10 mutations/Mb) or KRAS mutations had shorter progression-free survival (PFS) (hazard ratio [HR] 0.37, 0.14 to 0.97, P = 0.04; HR 0.23, 0.08 to 0.66, P < 0.01) and overall survival (OS) (HR 0.05, 0.01 to 0.35, P < 0.01; HR 0.22, 0.07 to 0.66, P < 0.01). In cohort 2 of the Qujing population, bTMB-H (≥ 6 mutations per Mb) and KRAS mutations were related to PFS (HR 0.59, 0.36 to 0.99, P = 0.04; HR 0.50, 0.26 to 0.98, P = 0.04) and OS (HR 0.58, 0.35 to 0.96, P = 0.03; HR 0.48, 0.25 to 0.93, P = 0.03). Notably, the Qujing population with bTMB-H had superior PFS (HR 0.32, 0.09 to 1.09, P = 0.01), OS (HR 0.33, 0.10 to 1.13, P < 0.01) and objective response rates (ORRs) (83.3% vs. 14.3% vs. 20.0%, P <0.01) to immunotherapy than other populations.ConclusionsThese findings show that tTMB, bTMB and KRAS mutations appear to be independent validated IRPSs that predict the clinical outcomes of Qujing populations with advanced NSCLC and that bTMB may be used as a reliable IRPS to predict the clinical benefit from anti-PD-1 therapies among populations from Qujing with advanced NSCLC.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1012166/fullimmune signaturepredictive biomarkerNSCLCimmunotherapyQujing |
| spellingShingle | Yuhui Ma Hutao Shi Guangqiang Zhao Xin Liu Jingjing Cai Guangjian Li Wanlin Chen Yujie Lei Lianhua Ye Chaojiang Fu Li Zhao Yongchun Zhou Yunchao Huang Yunchao Huang Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China Frontiers in Immunology immune signature predictive biomarker NSCLC immunotherapy Qujing |
| title | Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China |
| title_full | Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China |
| title_fullStr | Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China |
| title_full_unstemmed | Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China |
| title_short | Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China |
| title_sort | unique profile on the progress free survival and overall survival in patients with advanced non small cell lung cancer in the qujing area southwest china |
| topic | immune signature predictive biomarker NSCLC immunotherapy Qujing |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1012166/full |
| work_keys_str_mv | AT yuhuima uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT hutaoshi uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT guangqiangzhao uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT xinliu uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT jingjingcai uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT guangjianli uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT wanlinchen uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT yujielei uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT lianhuaye uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT chaojiangfu uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT lizhao uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT yongchunzhou uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT yunchaohuang uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina AT yunchaohuang uniqueprofileontheprogressfreesurvivalandoverallsurvivalinpatientswithadvancednonsmallcelllungcancerinthequjingareasouthwestchina |